{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T01:02:21Z","timestamp":1792890141564,"version":"4.5.0"},"reference-count":28,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"20","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["J Clin Oncol"],"published-print":{"date-parts":[[2026,7,10]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>\n                      The antibody-drug conjugate Temab-A comprises the c-Met\u2013targeting antibody telisotuzumab conjugated to a novel topoisomerase 1 inhibitor payload, adizutecan. A first-in-human phase I study (ClinicalTrials.gov identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT05029882\">NCT05029882<\/jats:ext-link>\n                      ) of Temab-A in patients with advanced solid tumors whose disease has progressed is currently ongoing. We report results from all patients in the dose escalation and the monotherapy metastatic colorectal cancer (mCRC) dose expansion.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>\n                      Temab-A was administered intravenously once every 3 weeks as a monotherapy starting at 1.6 mg\/kg in dose escalation. In mCRC dose expansion, patients with confirmed\n                      <jats:italic toggle=\"yes\">BRAF<\/jats:italic>\n                      wild-type, microsatellite stable\/mismatch repair-proficient mCRC were randomly assigned to 1.6 mg\/kg, 2.4 mg\/kg, or 3.0 mg\/kg Temab-A once every 3 weeks. Primary end points included safety, pharmacokinetics, recommended phase II dose of Temab-A monotherapy, and Temab-A efficacy in patients with mCRC.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>In total, 57 patients received \u22651 dose of Temab-A in dose escalation; 3.0 mg\/kg once every 3 weeks was established as the maximum tolerated dose. Collectively, in dose escalation and dose expansion, 122 patients with mCRC received Temab-A (dose escalation, N = 29; randomized dose optimization expansion, N = 93). All patients experienced \u22651 treatment-emergent adverse event; the most frequent were gastrointestinal (78%) and hematologic (71%) toxicities. Treatment-related discontinuations and deaths were infrequent (10% and 3%, respectively). Across all doses in patients with mCRC, overall response rate was 15.6% (95% CI, 9.6 to 23.2), disease control rate was 74.6% (95% CI, 65.9 to 82.0), and duration of response was 5.9 months (95% CI, 4.1 to 10.5); responses were more frequent at doses of 2.4 mg\/kg and 3.0 mg\/kg once every 3 weeks. Median progression-free survival was 4.6 months (95% CI: 4.0, 5.4), and median overall survival was 10.4 months (95% CI, 8.9 to 13.1).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Temab-A at 2.4 mg\/kg once every 3 weeks has a tolerable and manageable safety profile, with promising antitumor activity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco-25-01525","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T19:59:09Z","timestamp":1777665549000},"page":"1876-1888","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":3,"title":["Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors"],"prefix":"10.1200","volume":"44","clinical-trial-number":[{"clinical-trial-number":"nct05029882","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9769-0850","authenticated-orcid":true,"given":"Manish R.","family":"Sharma","sequence":"first","affiliation":[{"name":"START Center for Cancer Research\u2014Midwest, Grand Rapids, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7608-0380","authenticated-orcid":true,"given":"John","family":"Powderly","sequence":"additional","affiliation":[{"name":"Carolina BioOncology Institute, Huntersville, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3675-953X","authenticated-orcid":true,"given":"Yasutoshi","family":"Kuboki","sequence":"additional","affiliation":[{"name":"Department of Experimental Therapeutics, National Cancer Center Hospital East, Kashiwa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7579-1175","authenticated-orcid":true,"given":"John H.","family":"Strickler","sequence":"additional","affiliation":[{"name":"Duke University Medical Center, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7216-6577","authenticated-orcid":true,"given":"Ruth","family":"Perets","sequence":"additional","affiliation":[{"name":"Rambam Medical Center and Technion-Israel Institute of Technology, Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8120-3827","authenticated-orcid":true,"given":"Jonathan E.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Hadassah Hebrew University Medical Center, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Raimbourg","sequence":"additional","affiliation":[{"name":"Institut de Canc\u00e9rologie de l\u2019Ouest, Saint Herblain, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4589-2335","authenticated-orcid":true,"given":"Takako Eguchi","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Kyoto University Graduate School of Medicine, Kyoto-Shi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0787-2851","authenticated-orcid":true,"given":"Noboru","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcia","family":"Cruz-Correa","sequence":"additional","affiliation":[{"name":"The University of Puerto Rico, Medical Sciences Campus, and Pan-American Center for Oncology Trials, San Juan, Puerto Rico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bert","family":"O'Neil","sequence":"additional","affiliation":[{"name":"Oncology, Community Health Network North Cancer Center, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Ghiringhelli","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Centre Georges Fran\u00e7ois Leclerc, Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1311-4173","authenticated-orcid":true,"given":"Kanwal","family":"Raghav","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3504-0128","authenticated-orcid":true,"given":"Michael","family":"Cecchini","sequence":"additional","affiliation":[{"name":"Yale University School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1224-3646","authenticated-orcid":true,"given":"Jair","family":"Bar","sequence":"additional","affiliation":[{"name":"Jusidman Cancer Center, Sheba Medical Center, Ramat Gan, Israel"},{"name":"The Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2287-3392","authenticated-orcid":true,"given":"Zo\u00eb","family":"Hunter","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2686-059X","authenticated-orcid":true,"given":"Michael","family":"Burns","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Blaney","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2489-366X","authenticated-orcid":true,"given":"Gladys","family":"Morrison-Thiele","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6567-8782","authenticated-orcid":true,"given":"Martha Neagu","family":"Aristide","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7142-2444","authenticated-orcid":true,"given":"Kevin J.","family":"Freise","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Li","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Li","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athan","family":"Vasilopoulos","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6879-6557","authenticated-orcid":true,"given":"Carla","family":"Biesdorf","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7033-9064","authenticated-orcid":true,"given":"David","family":"Sommerhalder","sequence":"additional","affiliation":[{"name":"NEXT Oncology, San Antonio, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_13_2_2","first-page":"147","article-title":"Overexpression and amplification of the met\/HGF receptor gene during the progression of colorectal cancer","volume":"1","author":"Di Renzo MF","year":"1995","unstructured":"Di Renzo MF, Olivero M, Giacomini A, et al: Overexpression and amplification of the met\/HGF receptor gene during the progression of colorectal cancer. Clin Cancer Res 1:147-154, 1995","journal-title":"Clin Cancer Res"},{"key":"e_1_3_13_3_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15071976"},{"key":"e_1_3_13_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-5002(98)00007-5"},{"key":"e_1_3_13_5_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i12.3706"},{"key":"e_1_3_13_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2018.02.013"},{"key":"e_1_3_13_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/iep.12395"},{"key":"e_1_3_13_8_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21601"},{"key":"e_1_3_13_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2214963"},{"key":"e_1_3_13_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00772-9"},{"key":"e_1_3_13_11_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2138-z"},{"key":"e_1_3_13_12_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-19-0529"},{"key":"e_1_3_13_13_2","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2023-6311"},{"key":"e_1_3_13_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS3162"},{"key":"e_1_3_13_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.1314"},{"key":"e_1_3_13_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.1505"},{"key":"e_1_3_13_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/rssc.12089"},{"key":"e_1_3_13_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_3_13_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.09.444"},{"key":"e_1_3_13_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/26.4.404"},{"key":"e_1_3_13_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34507"},{"key":"e_1_3_13_22_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030713"},{"key":"e_1_3_13_23_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.923260"},{"key":"e_1_3_13_24_2","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25204764"},{"key":"e_1_3_13_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00470-8"},{"key":"e_1_3_13_26_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1568"},{"key":"e_1_3_13_27_2","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.4.2.219"},{"key":"e_1_3_13_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01419-6"},{"key":"e_1_3_13_29_2","doi-asserted-by":"publisher","DOI":"10.1021\/cb300648v"}],"updated-by":[{"DOI":"10.1200\/jco-26-01401","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000}}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO-25-01525","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T21:59:39Z","timestamp":1783634379000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO-25-01525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":28,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2026,7,10]]}},"alternative-id":["10.1200\/JCO-25-01525"],"URL":"https:\/\/doi.org\/10.1200\/jco-25-01525","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"assertion":[{"value":"2025-07-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-13","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}